Agios Pharmaceuticals Inc 2021 SR
The report highlights Agios Pharmaceuticals' commitment to cellular metabolism to treat genetically defined diseases. In 2020, the company announced a strategic shift to focus solely on genetically defined diseases, selling its oncology portfolio to Servier. Key achievements include positive Phase 3 data for mitapivat in PK deficiency and maintaining medicine supply during the COVID-19 pandemic. The report details progress in diversity, equity, and inclusion, including the formation of a DE&I Council and reporting that women comprise 57% of the total workforce. It also outlines environmental efforts such as waste reduction and energy-efficient facility upgrades.
Company: Agios Pharmaceuticals Inc
Sector: Health Care
Country: United States
Year: 2021
Type: SR
Pages: 36
Agios Pharmaceuticals Inc
ESG Report
The report highlights Agios Pharmaceuticals' commitment to cellular metabolism to treat genetically defined diseases. In 2020, the company announced a strategic shift to focus solely on genetically defined diseases, selling its oncology portfolio to Servier. Key achievements include positive Phase 3 data for mitapivat in PK deficiency and maintaining medicine supply during the COVID-19 pandemic. The report details progress in diversity, equity, and inclusion, including the formation of a DE&I Council and reporting that women comprise 57% of the total workforce. It also outlines environmental efforts such as waste reduction and energy-efficient facility upgrades.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management